Recombinant Anti-HER2 x Anti-HER3 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-HER2 specificity or anti-HER3 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.
Specifications
Type
scFv-based Bispecific Fragments
Application
FuncS; Promising therapeutic agent
Related Disease
Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors
Targets
Alternative Names
ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; human epidermal growth factor receptor 2; neuro/glioblastoma derived oncogene homolog; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Alternative Names
ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email
INQUIRY